

# CITATION REPORT

List of articles citing

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

DOI: 10.1038/leu.2016.192  
Leukemia, 2016, 30, 2133-2141.

**Source:** <https://exaly.com/paper-pdf/64649860/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
42	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3744-3755	12.9	13
41	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , <b>2017</b> , 129, e26-e37	2.2	107
40	Novel therapy for childhood acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1081-1099	4	19
39	The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations. <i>Molecular and Translational Medicine</i> , <b>2017</b> , 133-159	0.4	2
38	Dysregulation of BCL-2 family proteins by leukemia fusion genes. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 14325-14333	5.4	23
37	Emerging biological therapies to treat acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 107-121	3.7	13
36	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. <i>Future Oncology</i> , <b>2018</b> , 14, 2115-2129	3.6	27
35	Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells. <i>Cell Biology International</i> , <b>2018</b> , 42, 515-524	4.5	
34	The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 860-874	4	27
33	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2017773648	2.2	44
32	The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care. <i>EBioMedicine</i> , <b>2018</b> , 37, 205-213	8.8	4
31	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. <i>SLAS Discovery</i> , <b>2018</b> , 23, 732-741	3.4	4
30	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 239	8.4	26
29	Evolving paradigms for new agent development in pediatric oncology. <i>Current Opinion in Pediatrics</i> , <b>2018</b> , 30, 10-16	3.2	2
28	CD47-ligation induced cell death in T-acute lymphoblastic leukemia. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 544-9.8		25
27	Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , <b>2018</b> , 72, 59-66	2.7	6
26	Approach to the Adult Acute Lymphoblastic Leukemia Patient. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	11

25	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. <i>Blood</i> , <b>2019</b> , 134, 1257-1268	2.2	11
24	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , <b>2019</b> , 71, 671-697	22.5	8
23	The triviality of Brauer-Manin obstruction for subvarieties of semi-abelian varieties over function fields of characteristic zero. <i>Manuscripta Mathematica</i> , <b>2019</b> , 160, 385-389	0.5	
22	Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	49
21	Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway. <i>Biomedicine and Pharmacotherapy</i> , <b>2019</b> , 115, 108913	7.5	7
20	An improved advanced fragment analysis-based classification and risk stratification of pediatric acute lymphoblastic leukemia. <i>Cancer Cell International</i> , <b>2019</b> , 19, 110	6.4	0
19	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4493-4503	12.9	14
18	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. <i>Cancer Cell</i> , <b>2019</b> , 36, 660-673.e11	24.3	113
17	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 1524-1539	10.7	9
16	Development of an immune-related prognostic model for pediatric acute lymphoblastic leukemia patients. <i>Molecular Genetics &amp; Genomic Medicine</i> , <b>2020</b> , 8, e1404	2.3	2
15	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
14	Preferential Activity of Extract on Primary Myeloid Leukemic Blast. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2020</b> , 2020, 4736206	2.3	0
13	Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 742-751	8.7	0
12	A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks. <i>Scientific Reports</i> , <b>2020</b> , 10, 4192	4.9	3
11	Multi-Omics Analysis of Acute Lymphoblastic Leukemia Identified the Methylation and Expression Differences Between BCP-ALL and T-ALL. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 622393	5.7	2
10	Xenograft models for pediatric cancer therapies. <i>Faculty Reviews</i> , <b>2021</b> , 10, 11	1.2	1
9	Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
8	Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein. <i>Scientific Reports</i> , <b>2021</b> , 11, 10883	4.9	8

7	A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2021</b> ,	4.6	
6	Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric -Rearranged Acute Lymphoblastic Leukemia. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
5	Metformin dampens cisplatin cytotoxicity on leukemia cells after incorporation into cubosomal nanoformulation. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 143, 112140	7.5	2
4	Combining functional hairpin probes with disordered cleavage of CRISPR/Cas12a protease to screen for B lymphocytic leukemia.. <i>Biosensors and Bioelectronics</i> , <b>2022</b> , 201, 113941	11.8	0
3	PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets.		
2	Aryl hydrocarbon receptor $\beta$ ynurenine axis promotes oncogenic activity in BCP-ALL. <i>Cell Biology and Toxicology</i> ,	7.4	
1	The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.		0